Persons living with HIV are more likely to have tuberculosis (TB) disease attributed to recent transmission (RT) and to die during TB treatment than persons without HIV. We examined factors associated with RT or mortality among TB/HIV patients.
Using National TB Surveillance System data from 2011 to 2016, we calculated multivariable adjusted odds ratios (aOR) with 99% confidence intervals (CI) to estimate associations between patient characteristics and RT or mortality. Mortality analyses were restricted to 2011–2014 to allow sufficient time for reporting outcomes.
TB disease was attributed to RT in 491 (20%) of 2415 TB/HIV patients. RT was more likely among those reporting homelessness (aOR, 2.6; CI, 2.0, 3.5) or substance use (aOR,1.6; CI, 1.2, 2.1) and among blacks (aOR,1.8; CI, 1.2, 2.8) and Hispanics (aOR, 1.8; CI, 1.1, 2.9); RT was less likely among non-US-born persons (aOR, 0.2; CI, 0.2, 0.3). The proportion who died during TB treatment was higher among persons with HIV than without (8.6% versus 5.2%; p < 0.0001). Among 2273 TB/HIV patients, 195 died during TB treatment. Age ≥ 65 years (aOR, 5.3; CI, 2.4, 11.6), 45–64 years (aOR, 2.2; CI, 1.4, 3.4), and having another medical risk factor for TB (aOR, 3.3; CI, 1.8, 6.2) were associated with death; directly observed treatment (DOT) for TB was protective (aOR, 0.5; CI, 0.2, 1.0).
Among TB/HIV patients, blacks, Hispanics, and those reporting homelessness or substance use should be prioritized for interventions that decrease TB transmission. Improved adherence to treatment through DOT was associated with decreased mortality, but additional interventions are needed to reduce mortality among older patients and those TB/HIV patients with another medical risk factor for TB.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
World Health Organization. Global Tuberculosis Report 2017. Geneva, World Health Organization; 2018. Available from: https://www.who.int/tb/publications/global_report/en/. Date last accessed 8 Mar 2019.
Beavers SF, Pascopella L, Davidow AL, Tuberculosis Epidemiologic Studies Consortium, et al. Tuberculosis mortality in the United States: epidemiology and prevention opportunities. Ann Am Thorac Soc. 2018. https://doi.org/10.1513/AnnalsATS.201705-405OC.
Nahid P, Jarlsberg LG, Rudoy I, et al. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis. 2011. https://doi.org/10.1186/1471-2334-11-1.
Marks SM, Magee E, Robison V. Patients diagnosed with tuberculosis at death or who died during therapy: association with the human immunodeficiency virus. Int J Tuberc Lung Dis. 2011;15(4):465–70.
Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV co-infection. PLoS Pathog. 2012;8(2):e1002464.
Schutz C, Meintjes G, Almajid F, Wilkinson RI, Pozniak A. Clinical management of tuberculosis and HIV-1 co-infection. Eur Respir J. 2010;36:1460–81.
Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis. 2010;14(10):1295–302.
Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis. 2007;1(suppl 196):S15–27.
CDC. Reported tuberculosis in the United States, 2017. Atlanta: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/tb/statistics/reports/2017/2017_Surveillance_FullReport.pdf. Accessed 30 June 2019
Albalak R, O’Brien RJ, Kammerer S, et al. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. Arch Intern Med. 2007;167(22):2443–51.
France AM, Grant J, Kammerer JS, Navin TR. A field-validated approach using surveillance and genotyping data to estimate tuberculosis attributable to recent transmission in the United States. Am J Epidemiol. 2015;182:799–807.
Hannah HA, Miramontes R, Gandhi NR. Sociodemographic and clinical risk factors associated with tuberculosis mortality in the United States, 2009-2013. Public Health Rep. 2017;132(3):366–75.
Ribeiro PF, Gange SJ, Horberg MA, et al. Geographic variations in retention in care among HIV-infected adults in the United States. PLoS One. 2016;11(1):e0146119.
CDC. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009;58(1):7–10 http://www.ncbi.nlm.nih.gov/pubmed/19145221. Accessed 30 June 2019
Ngwira LF, Corbett EL, Khundi M, et al. Screening for tuberculosis with Xpert MTB/RIF assay versus fluorescent microscopy among adults newly diagnosed with human immunodeficiency virus in rural Malawi: a cluster randomized trial (Chepetsa). Clin Infect Dis. 2019;68(7):1176–83.
Yuen CM, Kammerer JS, Marks K, Navin TR, France AM. Recent transmission of tuberculosis — United States, 2011–2014. PLoS One. 2016;11(4):e0153728.
Bamrah S, Yelk Woodruff RS, Powell K, Ghosh S, Kammerer JS, Haddad MB. Tuberculosis among the homeless, United States, 1994-2010. Int J Tuberc Lung Dis. 2013 Nov;17(11):1414–9.17.
Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med. 2009;169:189–97.
Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005–2009. PLoS One. 2011;6(11):e27405.
Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated Rate of Reactivation of Latent Tuberculosis Infection in the United States, Overall and by Population Subgroup. Am J Epidemiol. 2013. https://doi.org/10.1093/aje/kwt246.
Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–207 https://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm?s_cid=rr58e324a1_e. Accessed 30 June 2019
García-García M, Ponce-de-León A, García-Sancho MC, et al. Tuberculosis-related deaths within a well-functioning DOTS control program. Emerg Infect Dis. 2002;8(11):1327–33. https://doi.org/10.3201/eid0811.020021.
Conflict of Interest
The authors declare that they have no conflict of interest.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Schmit, K.M., Shah, N., Kammerer, S. et al. Tuberculosis Transmission or Mortality Among Persons Living with HIV, USA, 2011–2016. J. Racial and Ethnic Health Disparities (2020). https://doi.org/10.1007/s40615-020-00709-7